02 9541 3500
UNSW RNA Institute making next generation RNA therapeutics and vaccines using Micropore Pathfinder
We are excited to share the news – Micropore Technologies Ltd Pathfinder PRO 250 is ready at the UNSW
The Key Considerations For Developing Lnps As Drug Delivery Vehicles.
Lipid Nanoparticles (LNPs) continue to grow in popularity as they enable the efficient delivery of therapeutic
Next Generation LNP Manufacturing
Ease of scalability Producing COVID-19 vaccines for the entire world population rapidly demonstrated the
Brownian Motion
What is Brownian Motion and Why Is It Important? In 1827, Scottish botanist Robert Brown looked through
The power of orthogonal approaches to accelerate development of targeted therapies
A common challenge found in the world of scientific research is achieving recognition for topics not typically
Ready to Watch Webinars focused on particle characterisation: Tips and tricks
These webinars are designed for you to sharpen your analytical methods, deepen your knowledge, or
Scaling non-viral gene delivery from preclinical stages to commercial manufacturing
Lipid-based genetic medicines have garnered recent attention with the expedited creation of COVID-19 vaccines
Let’s build mRNA vaccine formulation and manufacturing capability locally in Australia
A new age of mRNA vaccine development upon us. As a COVAX member, Australia will have access to buy
Develop and Manufacture RNA Medicines for the Treatment of COVID-19 faster and more reliably
Learn how the PNI NanoAssemblr Ignite supports: 1. Development of COVID-19 RNA-LNP vaccine2. Proprietary